{"id":126,"text":"Green tea (GT) alters the disposition of a number of drugs, such as nadolol and lisinopril.","label":[[0,14,"Herb name"],[68,75,"Drug"],[80,90,"Drug"]],"Comments":[]}
{"id":127,"text":"However, it is unknown whether GT affects disposition of hydrophilic anti‐allergic drugs.","label":[[31,33,"Herb name"],[69,88,"Drug"]],"Comments":[]}
{"id":128,"text":"The purpose of this study was to investigate whether pharmacokinetics of fexofenadine and pseudoephedrine are affected by catechins, major GT components.","label":[[73,85,"Drug"],[90,105,"Drug"],[122,152,"Herb name"],[139,141,"Herb name"]],"Comments":[]}
{"id":129,"text":"A randomized, open, 2‐phase crossover study was conducted in 10 healthy Japanese volunteers.","label":[[2,43,"Study"],[61,91,"Cohort"],[64,71,"Pathology"],[72,80,"Ethnic group"]],"Comments":[]}
{"id":130,"text":"After overnight fasting, subjects were simultaneously administered fexofenadine (60 mg) and pseudoephedrine (120 mg) with an aqueous solution of green tea extract (GTE) containing (−)‐epigallocatechin gallate (EGCG) of ~ 300 mg or water (control).","label":[[67,79,"Drug"],[81,86,"Amount"],[92,107,"Drug"],[109,115,"Amount"],[125,168,"Extraction process"],[145,168,"Herb name"],[180,215,"Herb name"],[219,227,"Amount"]],"Comments":[]}
{"id":131,"text":"In vitro transport assays were performed using HEK293 cells stably expressing organic anion transporting polypeptide (OATP)1A2 to evaluate the inhibitory effect of EGCG on OATP1A2‐mediated fexofenadine transport.","label":[[164,168,"Herb name"],[172,179,"Target"],[172,211,"Parameter"],[189,201,"Drug"]],"Comments":[]}
{"id":132,"text":"In the GTE phase, the area under the plasma concentration‐time curve and the amount excreted unchanged into urine for 24 hours of fexofenadine were significantly decreased by 70% (P < 0.001) and 67% (P < 0.001), respectively, compared with control.","label":[[7,10,"Herb name"],[18,68,"Parameter"],[73,113,"Parameter"],[114,126,"Duration"],[130,142,"Drug"],[175,178,"Amount"],[195,198,"Amount"]],"Comments":[]}
{"id":133,"text":"There were no differences in time to maximum plasma concentration and the elimination half‐life of fexofenadine between phases.","label":[[37,65,"Parameter"],[70,95,"Parameter"],[99,111,"Drug"]],"Comments":[]}
{"id":134,"text":"Fexofenadine was confirmed to be a substrate of OATP1A2, and EGCG (100 and 1,000 μM) and GTE (0.1 and 1 mg\/mL) inhibited OATP1A2‐mediated uptake of fexofenadine.","label":[[0,12,"Drug"],[48,55,"Target"],[61,65,"Herb name"],[67,70,"Amount"],[75,83,"Amount"],[89,92,"Herb name"],[94,97,"Amount"],[102,109,"Amount"],[121,128,"Target"],[121,160,"Parameter"],[149,160,"Drug"]],"Comments":[]}
{"id":135,"text":"On the contrary, the concomitant administration of GTE did not influence the pharmacokinetics of pseudoephedrine.","label":[[51,54,"Herb name"],[97,112,"Drug"]],"Comments":[]}
{"id":136,"text":"These results suggest that intake of GT may result in a markedly reduced exposure of fexofenadine, but not of pseudoephedrine, putatively by inhibiting OATP1A2‐mediated intestinal absorption.","label":[[37,39,"Herb name"],[85,97,"Drug"],[110,125,"Drug"],[152,159,"Target"],[152,190,"Parameter"]],"Comments":[]}
{"id":137,"text":"WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?","label":[],"Comments":[]}
{"id":138,"text":"☑ Green tea (GT) and its catechin components interact with hydrophilic drugs, such as nadolol and lisinopril.","label":[[2,16,"Herb name"],[25,33,"Herb name"],[86,93,"Drug"],[98,108,"Drug"]],"Comments":[]}
{"id":139,"text":"A combination of fexofenadine and pseudoephedrine is clinically available for treatment of allergic rhinitis.","label":[[17,29,"Drug"],[34,49,"Drug"],[91,108,"Pathology"]],"Comments":[]}
{"id":140,"text":"WHAT QUESTION DID THIS STUDY ADDRESS?","label":[],"Comments":[]}
{"id":141,"text":"☑ This study evaluated whether pharmacokinetics of fexofenadine and pseudoephedrine are affected when orally administered with an aqueous solution of green tea extract (GTE) in healthy volunteers.","label":[[51,63,"Drug"],[68,83,"Drug"],[130,173,"Extraction process"],[150,173,"Herb name"],[177,184,"Pathology"]],"Comments":[]}
{"id":142,"text":"WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?","label":[],"Comments":[]}
{"id":143,"text":"☑ Plasma concentrations and urinary excretions of fexofenadine were markedly decreased when coadministered with GTE, containing ~ 300 mg of (−)‐epigallocatechin gallate.","label":[[2,23,"Parameter"],[28,46,"Parameter"],[50,62,"Drug"],[112,115,"Herb name"],[128,136,"Amount"],[140,168,"Herb name"]],"Comments":[]}
{"id":144,"text":"GTE and (−)‐epigallocatechin gallate significantly inhibited OATP1A2‐mediated fexofenadine uptake.","label":[[0,3,"Herb name"],[8,36,"Herb name"],[61,68,"Target"],[61,97,"Parameter"],[78,90,"Drug"]],"Comments":[]}
{"id":145,"text":"No differences were observed in the pharmacokinetics of pseudoephedrine between water and GTE.","label":[[56,71,"Drug"],[90,93,"Herb name"]],"Comments":[]}
{"id":146,"text":"HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?","label":[],"Comments":[]}
{"id":147,"text":"☑ GT and its catechin supplement reduce oral bioavailability of fexofenadine, but not of pseudoephedrine.","label":[[2,4,"Herb name"],[13,21,"Herb name"],[40,76,"Parameter"],[64,76,"Drug"],[89,104,"Drug"]],"Comments":[]}
{"id":148,"text":"The inhibition of intestinal OATP1A2 by (−)‐epigallocatechin gallate is a likely mechanism underlying this interaction.","label":[[18,36,"Target"],[40,68,"Herb name"]],"Comments":[]}
{"id":149,"text":"Green tea (GT; Camellia sinensis) and its main components, catechins, are perpetrators of clinically relevant food‐drug interactions with hydrophilic and nonmetabolized drugs, such as nadolol and lisinopril.","label":[[0,33,"Herb name"],[59,68,"Herb name"],[184,191,"Drug"],[196,206,"Drug"]],"Comments":[]}
{"id":150,"text":"The H At present, a combined tablet of fexofenadine and pseudoephedrine, a nasal decongestant, is available for the treatment of allergic rhinitis in several countries, such as the United States (Allegra‐D) and Japan (Dellegra).","label":[[39,51,"Drug"],[56,71,"Drug"],[129,146,"Pathology"],[196,205,"Drug"],[218,226,"Drug"]],"Comments":[]}
{"id":151,"text":"Taking into account the anti‐allergic potential of GT and catechins,  Ten healthy nonsmoking Japanese volunteers (8 men and 2 women) participated in this study with an age range of 21–45 years and body mass index of 18.4–26.0 kg\/m The study protocol was approved by the ethics committee of the Fukushima Medical University (approval number: RK29037) and was registered at the UMIN Clinical Trials Registry (UMIN000032828).","label":[[51,53,"Herb name"],[58,67,"Herb name"],[70,132,"Cohort"],[74,92,"Pathology"],[93,101,"Ethnic group"],[116,119,"Sex"],[126,131,"Sex"],[172,192,"Age"],[197,212,"Parameter"],[216,230,"Amount"],[381,396,"Study"]],"Comments":[]}
{"id":152,"text":"The study was conducted in compliance with the principles of the Declaration of Helsinki.","label":[],"Comments":[]}
{"id":153,"text":"In a single‐center, open‐label, randomized 2‐way crossover study with a washout period of 2 weeks, the participants ingested a single oral dose of 2 tablets of fexofenadine (30 mg × 2) and (+)‐pseudoephedrine (sustained‐release formulation, 60 mg × 2; Dellegra; LTL Pharma, Tokyo, Japan) simultaneously with 150 mL of an aqueous solution of a commercial GTE (Sunphenon‐EGCG, Taiyo Kagaku, Yokkaichi, Japan) or with 150 mL of water after overnight fasting.","label":[[3,64,"Study"],[80,97,"Duration"],[147,156,"Amount"],[160,172,"Drug"],[174,183,"Amount"],[189,239,"Drug"],[241,250,"Amount"],[252,260,"Drug"],[308,314,"Amount"],[321,357,"Extraction process"],[354,357,"Herb name"],[359,373,"Herb name"],[415,421,"Amount"]],"Comments":[]}
{"id":154,"text":"The GTE contained 92.5% (w\/w) of EGCG, and 325 mg of which was dissolved in water with stirring.","label":[[4,7,"Herb name"],[18,29,"Amount"],[33,37,"Herb name"],[43,49,"Amount"]],"Comments":[]}
{"id":155,"text":"Subjects had a snack at 1 hour and a standardized meal at 4 hours after administration.","label":[[24,30,"Duration"],[58,65,"Duration"]],"Comments":[]}
{"id":156,"text":"In each study period, 5 mL venous blood samples were collected from an indwelling catheter placed in an antecubital vein or by direct venipuncture into EDTA‐treated tubes at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after administration.","label":[[22,26,"Amount"],[209,217,"Duration"]],"Comments":[]}
{"id":157,"text":"Blood samples were immediately centrifuged at 2,000 g for 10 minutes at 4°C.","label":[[46,53,"Amount"],[58,68,"Duration"],[72,75,"Parameter"]],"Comments":[]}
{"id":158,"text":"Urine was collected during periods of 0–4, 4–8, and 8–24 hours after administration.","label":[[38,41,"Duration"],[43,46,"Duration"],[52,62,"Duration"]],"Comments":[]}
{"id":159,"text":"Plasma and urine samples were stored at −80°C until analysis.","label":[[40,45,"Parameter"]],"Comments":[]}
{"id":160,"text":"The concentrations of fexofenadine and pseudoephedrine in plasma and urine were determined using ultra‐performance liquid chromatography (UPLC) with fluorescence detection (UPLC, Waters, Milford, MA), as summarized in  Methods S1 .","label":[[22,34,"Drug"],[39,54,"Drug"]],"Comments":[]}
{"id":161,"text":"Diphenhydramine and phenylephrine were used as internal standards for fexofenadine and pseudoephedrine, respectively.","label":[[0,15,"Drug"],[20,33,"Drug"],[70,82,"Drug"],[87,102,"Drug"]],"Comments":[]}
{"id":162,"text":"The limit of quantification for fexofenadine and pseudoephedrine was both 10 ng\/mL.","label":[[32,44,"Drug"],[49,64,"Drug"],[74,82,"Amount"]],"Comments":[]}
{"id":163,"text":"The inter‐day coefficients of variation of fexofenadine and pseudoephedrine were 9.9% and 7.3%, respectively.","label":[[43,55,"Drug"],[60,75,"Drug"],[81,85,"Amount"],[90,94,"Amount"]],"Comments":[]}
{"id":164,"text":"To test whether GTE and EGCG affect OATP1A2‐ and OATP2B1‐mediated uptake of fexofenadine, we performed in vitro transport assays using OATP1A2‐ and OATP2B1‐stably expressing HEK cells and the respective HEK‐VC vector control cells.","label":[[16,19,"Herb name"],[24,28,"Herb name"],[36,43,"Target"],[49,56,"Target"],[49,88,"Parameter"],[76,88,"Drug"]],"Comments":[]}
{"id":165,"text":"Sulfobromophthalein (BSP) was used as a typical substrate for OATP2B1.","label":[[0,25,"Drug"],[62,69,"Target"]],"Comments":[]}
{"id":166,"text":"The transporter‐expressing cells and the respective vector control cells were cultured according to previous studies.","label":[],"Comments":[]}
{"id":167,"text":"To examine the possibility of direct chemical binding between fexofenadine and EGCG in the gastrointestinal tract, fexofenadine (400 μg\/mL, based on the maximum concentration when a 60‐mg dose was dissolved in 150 mL) was incubated in the presence or absence of EGCG (1 mg\/mL) in saline at 37°C for 1, 2, and 24 hours.","label":[[62,74,"Drug"],[79,83,"Herb name"],[115,127,"Drug"],[129,138,"Amount"],[182,187,"Amount"],[210,216,"Amount"],[262,266,"Herb name"],[268,275,"Amount"],[290,294,"Parameter"],[299,300,"Duration"],[302,303,"Duration"],[309,317,"Duration"]],"Comments":[]}
{"id":168,"text":"Bortezomib (20 μg\/mL) was used as a positive control for the chemical interaction with EGCG.","label":[[0,10,"Drug"],[12,20,"Amount"],[87,91,"Herb name"]],"Comments":[]}
{"id":169,"text":"The chromatographic separation of the samples was achieved by UPLC (Waters) system, as stated in detail in  Methods S1 .","label":[],"Comments":[]}
{"id":170,"text":"The peak plasma concentration (C   In vitro data are expressed as mean ± standard error mean.","label":[[0,32,"Parameter"]],"Comments":[]}
{"id":171,"text":"Clinical pharmacokinetic data are expressed as geometric means and coefficient of variation (geoCV, %) unless otherwise noted.","label":[],"Comments":[]}
{"id":172,"text":"The number of subjects was deemed to be sufficient to detect a potentially clinically meaningful effect size of 35% difference in AUC All participants completed the study.","label":[[112,115,"Amount"],[130,133,"Parameter"]],"Comments":[]}
{"id":173,"text":"None of the subjects experienced any adverse events related to the drugs.","label":[[37,51,"Pathology"]],"Comments":[]}
{"id":174,"text":"Three individuals were genotyped as SLCO2B1 c.1457CC (*1\/*1) carriers, 5 individuals as SLCO2B1 c.1457CT (*1\/*3) carriers, and 2 individuals as SLCO2B1 c.1457TT (*3\/*3) carriers.","label":[],"Comments":[]}
{"id":175,"text":"Plasma concentration‐time profiles and pharmacokinetic parameters of fexofenadine are shown in Figure  1  and Table  1 .","label":[[0,34,"Parameter"],[69,82,"Drug"]],"Comments":[]}
{"id":176,"text":"There were no apparent differences in pharmacokinetic parameters of fexofenadine stratified for SLCO2B1 *3 SNV in water (control) phase (data not shown).","label":[[68,80,"Drug"]],"Comments":[]}
{"id":177,"text":"Fexofenadine C  Plasma concentration profile of fexofenadine after oral administration of fexofenadine (60 mg) with 150 mL of an aqueous solution of (−)‐epigallocatechin gallate (EGCG)‐concentrated green tea extract (○), or water (●) in 10 healthy volunteers.","label":[[0,12,"Drug"],[16,60,"Parameter"],[48,60,"Drug"],[90,102,"Drug"],[104,109,"Amount"],[116,122,"Amount"],[129,215,"Extraction process"],[149,184,"Herb name"],[198,207,"Herb name"],[237,258,"Cohort"],[240,247,"Pathology"]],"Comments":[]}
{"id":178,"text":"Data are expressed as the arithmetic mean ± SD.","label":[],"Comments":[]}
{"id":179,"text":"The inset is the log‐concentration vs. time profile.","label":[],"Comments":[]}
{"id":180,"text":"Pharmacokinetic parameters of fexofenadine after oral administration with GTE or water in healthy volunteers Fexofenadine (60 mg) was orally administered with water (150 mL), or an aqueous solution of EGCG‐concentrated green tea extract (150 mL) in 10 healthy Japanese volunteers.","label":[[30,42,"Drug"],[74,77,"Herb name"],[90,97,"Pathology"],[109,121,"Drug"],[123,128,"Amount"],[166,172,"Amount"],[178,236,"Extraction process"],[201,205,"Herb name"],[219,228,"Herb name"],[238,244,"Amount"],[249,279,"Cohort"],[252,259,"Pathology"],[260,268,"Ethnic group"]],"Comments":[]}
{"id":181,"text":"The T   A  Urinary excretion of fexofenadine after oral administration of fexofenadine (60 mg) with 150 mL of an aqueous solution of (−)‐epigallocatechin gallate (EGCG)‐concentrated green tea extract (○), or water (●) in 10 healthy volunteers.","label":[[0,44,"Parameter"],[32,44,"Drug"],[74,86,"Drug"],[88,93,"Amount"],[100,106,"Amount"],[113,199,"Extraction process"],[133,168,"Herb name"],[182,191,"Herb name"],[221,242,"Cohort"],[224,231,"Pathology"]],"Comments":[]}
{"id":182,"text":"(a) Cumulative urinary excretion (mg) of fexofenadine over 24 hours after administration, (b) % of dose, and (c) renal clearance (CL Plasma concentration‐time profiles and pharmacokinetic parameters of pseudoephedrine are shown in Figure  3  and Table  2 .","label":[[4,53,"Parameter"],[41,53,"Drug"],[59,67,"Duration"],[94,103,"Parameter"],[113,132,"Parameter"],[133,167,"Parameter"],[202,217,"Drug"]],"Comments":[]}
{"id":183,"text":"No differences were observed in any pharmacokinetic parameters of pseudoephedrine, including AUC, T  Plasma concentration profile of pseudoephedrine after oral administration of pseudoephedrine (120 mg) with 150 mL of an aqueous solution of (−)‐epigallocatechin gallate (EGCG)‐concentrated green tea extract (○), or water (●) in 10 healthy volunteers.","label":[[66,81,"Drug"],[93,96,"Parameter"],[98,148,"Parameter"],[133,148,"Drug"],[178,193,"Drug"],[195,201,"Amount"],[208,214,"Amount"],[221,307,"Extraction process"],[241,276,"Herb name"],[290,299,"Herb name"],[329,350,"Cohort"],[332,339,"Pathology"]],"Comments":[]}
{"id":184,"text":"Data are expressed as the arithmetic mean ± SD.","label":[],"Comments":[]}
{"id":185,"text":"The inset is the log‐concentration vs. time profile.","label":[],"Comments":[]}
{"id":186,"text":"Pharmacokinetic parameters of pseudoephedrine after oral administration with GTE or water in healthy volunteers Pseudoephedrine (120 mg) was orally administered with water (150 mL), or an aqueous solution of EGCG‐concentrated green tea extract (150 mL) in 10 healthy Japanese volunteers.","label":[[30,45,"Drug"],[77,80,"Herb name"],[93,100,"Pathology"],[112,127,"Drug"],[129,135,"Amount"],[173,179,"Amount"],[185,243,"Extraction process"],[208,212,"Herb name"],[226,235,"Herb name"],[245,251,"Amount"],[256,286,"Cohort"],[259,266,"Pathology"],[267,275,"Ethnic group"]],"Comments":[]}
{"id":187,"text":"The T   A  Urinary excretion of pseudoephedrine after oral administration of pseudoephedrine (120 mg) with 150 mL of an aqueous solution of (−)‐epigallocatechin gallate (EGCG)‐concentrated green tea extract (GTE; ○), or water (●) in 10 healthy volunteers.","label":[[0,47,"Parameter"],[32,47,"Drug"],[77,92,"Drug"],[94,100,"Amount"],[107,113,"Amount"],[120,211,"Extraction process"],[170,174,"Herb name"],[189,211,"Herb name"],[233,254,"Cohort"],[236,244,"Pathology"]],"Comments":[]}
{"id":188,"text":"(a) Cumulative urinary excretion (mg) of pseudoephedrine over 24 hours after administration, (b) percent of dose, and (c) renal clearance (CL Cellular accumulation of fexofenadine (10 μM) in HEK‐OATP1A2 cells was 22.14‐fold higher than that in vector control (PQX) cells (P < 0.01) at pH 7.3.","label":[[4,56,"Parameter"],[41,56,"Drug"],[62,70,"Duration"],[97,112,"Parameter"],[122,141,"Parameter"],[142,179,"Parameter"],[167,179,"Drug"],[181,186,"Amount"],[213,223,"Amount"],[285,291,"Parameter"]],"Comments":[]}
{"id":189,"text":"Moreover, OATP1A2‐mediated fexofenadine uptake was nearly completely inhibited in the presence of EGCG (100 μM and 1 mM) or GTE (0.1 and 1 mg\/mL; P < 0.01; Figure  5 a ).","label":[[10,17,"Target"],[10,46,"Parameter"],[27,39,"Drug"],[98,102,"Herb name"],[104,110,"Amount"],[115,119,"Amount"],[124,127,"Herb name"],[129,132,"Amount"],[137,144,"Amount"]],"Comments":[]}
{"id":190,"text":"On the other hand, only slight but significant uptake of fexofenadine (10 μM) mediated by OATP2B1 was observed in HEK‐OATP2B1 cells compared with vector control cells at both pH 6.3 and pH 7.3 (Figure  S3 ), which is in accordance with recent papers.","label":[[47,97,"Parameter"],[57,69,"Drug"],[71,76,"Amount"],[175,181,"Parameter"],[186,192,"Parameter"]],"Comments":[]}
{"id":191,"text":"In vitro uptake assays of fexofenadine in HEK‐OATP1A2 cells or sulfobromophthalein (BSP) in HEK‐OATP2B1 cells (black bars), and in the respective HEK control cells (PQX) for OATP1A2 or (VC) for OATP2B1 (white bars).","label":[[26,38,"Drug"],[63,88,"Drug"]],"Comments":[]}
{"id":192,"text":"Cellular accumulation of 10 μM fexofenadine at pH 7.3 (a), or 1 μM BSP at pH 7.3 (b) and pH 6.3 (c) after 10 minutes incubation was measured by liquid chromatography–tandem mass spectrometry (LC–MS\/MS) (fexofenadine) or liquid scintillation counting (BSP) in the presence or absence of (−)‐epigallocatechin gallate (EGCG at 100 and 1,000 μM) or EGCG‐concentrated green tea extract (GTE at 0.1 and 1 mg\/mL) used in the clinical study.","label":[[0,43,"Parameter"],[25,30,"Amount"],[31,43,"Drug"],[47,53,"Parameter"],[62,66,"Amount"],[67,70,"Drug"],[74,80,"Parameter"],[89,95,"Parameter"],[106,116,"Duration"],[203,215,"Drug"],[251,254,"Drug"],[286,320,"Herb name"],[324,327,"Amount"],[332,340,"Amount"],[345,349,"Herb name"],[345,385,"Extraction process"],[363,385,"Herb name"],[389,392,"Amount"],[397,404,"Amount"],[418,432,"Study"]],"Comments":[]}
{"id":193,"text":"Data are presented as mean ± SEM.","label":[],"Comments":[]}
{"id":194,"text":"(n = 6).","label":[[5,6,"Amount"]],"Comments":[]}
{"id":195,"text":"**P < 0.01, vs. uptake into HEK293 control cells (PQX or VC);  It has been reported that GT catechins chemically interacted with various kinds of drugs including bortezomib, a proteasome inhibitor (Figure  S4  a).","label":[[89,101,"Herb name"],[162,196,"Drug"]],"Comments":[]}
{"id":196,"text":"In this study, we report that a single concomitant ingestion of an aqueous solution (150 mL) of GTE containing about 300 mg of EGCG (~ 4.4 mM), significantly decreases plasma concentrations and urinary excretion of fexofenadine when compared with water (control) in healthy volunteers (Figures 1, 2).","label":[[67,99,"Extraction process"],[85,91,"Amount"],[96,99,"Herb name"],[117,123,"Amount"],[127,131,"Herb name"],[133,141,"Amount"],[168,189,"Parameter"],[194,227,"Parameter"],[215,227,"Drug"],[266,273,"Pathology"]],"Comments":[]}
{"id":197,"text":"In contrast, no substantial differences were observed in the pharmacokinetics of pseudoephedrine between GTE and control phases (Figures 3, 4).","label":[[81,96,"Drug"],[105,108,"Herb name"]],"Comments":[]}
{"id":198,"text":"Fexofenadine and pseudoephedrine have common properties in terms of high hydrophilicity and negligible oxidative metabolism in the body, whereas the oral bioavailability of fexofenadine (35%) is considerably lower than that of pseudoephedrine (≈100%).","label":[[0,12,"Drug"],[17,32,"Drug"],[145,185,"Parameter"],[173,185,"Drug"],[187,190,"Amount"],[219,242,"Parameter"],[227,242,"Drug"],[244,249,"Amount"]],"Comments":[]}
{"id":199,"text":"Regarding the molecular mechanisms for reduced exposure of fexofenadine after oral administration, it is well known that the intestinal absorption of fexofenadine is highly dependent on transporter‐mediated uptake and\/or efflux, and that inhibition of the relevant transporters by co‐administered drugs or food could result in a significant impact on its pharmacokinetics.","label":[[59,71,"Drug"],[121,162,"Parameter"],[150,162,"Drug"]],"Comments":[]}
{"id":200,"text":"A second possible mechanism is a direct chemical interaction between fexofenadine and EGCG.","label":[[69,82,"Drug"],[86,90,"Herb name"]],"Comments":[]}
{"id":201,"text":"Indeed, various drugs, including aripiprazole, bortezomib, cetirizine, and sunitinib, has been reported to interact with EGCG.","label":[[33,45,"Drug"],[47,57,"Drug"],[59,69,"Drug"],[75,84,"Drug"],[121,125,"Herb name"]],"Comments":[]}
{"id":202,"text":"In contrast to fexofenadine, the plasma concentration‐time profile and cumulative urinary excretions of pseudoephedrine were similar in both phases, suggesting that EGCG had no impact on pseudoephedrine pharmacokinetics (Figures 3, 4).","label":[[15,27,"Drug"],[29,66,"Parameter"],[71,119,"Parameter"],[104,119,"Drug"],[165,169,"Herb name"],[187,202,"Drug"]],"Comments":[]}
{"id":203,"text":"Due to high solubility and low permeability, pseudoephedrine was provisionally classified as BCS class 3 drug.","label":[[45,60,"Drug"]],"Comments":[]}
{"id":204,"text":"A limitation of this study is that all volunteers were Japanese, so it remains unclear whether ethnic differences effect pharmacokinetic interactions between GT and fexofenadine.","label":[[55,63,"Ethnic group"],[158,160,"Herb name"],[165,177,"Drug"]],"Comments":[]}
{"id":205,"text":"In relation to ethnicity, there was no influence of the SLCO2B1*3 SNV on fexofenadine pharmacokinetics, although we confirmed that this polymorphism is common in Japanese population.","label":[[73,85,"Drug"],[162,170,"Ethnic group"]],"Comments":[]}
{"id":206,"text":"In conclusion, we show for the first time that co‐administration of GTE markedly reduces exposure to fexofenadine in humans by inhibiting OATP1A2‐mediated intestinal absorption, whereas the pharmacokinetics of pseudoephedrine are unlikely to be influenced by co‐administration of GTE.","label":[[68,71,"Herb name"],[101,113,"Drug"],[138,145,"Target"],[138,176,"Parameter"],[210,225,"Drug"],[280,283,"Herb name"]],"Comments":[]}
{"id":207,"text":"Considering that brewed GT contains more catechins and flavonoids in addition to EGCG, we propose that GT should not be taken during anti‐allergic therapy using, at least, fexofenadine.","label":[[24,27,"Herb name"],[41,50,"Herb name"],[55,65,"Herb name"],[81,85,"Herb name"],[103,105,"Herb name"],[133,154,"Drug"],[172,184,"Drug"]],"Comments":[]}
{"id":208,"text":"This study was partly supported by JSPS KAKENHI Grant Number 17K17983 and 17K08949.","label":[],"Comments":[]}
{"id":209,"text":"The authors declared no competing interests for this work.","label":[],"Comments":[]}
{"id":210,"text":"S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.","label":[],"Comments":[]}
{"id":211,"text":"wrote the manuscript.","label":[],"Comments":[]}
{"id":212,"text":"S.M., J.K., H.W., M.F., and K.S.","label":[],"Comments":[]}
{"id":213,"text":"designed the research.","label":[],"Comments":[]}
{"id":214,"text":"S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.","label":[],"Comments":[]}
{"id":215,"text":"performed the research.","label":[],"Comments":[]}
{"id":216,"text":"S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.","label":[],"Comments":[]}
{"id":217,"text":"analyzed the data.","label":[],"Comments":[]}
{"id":218,"text":"Figure S1  Click here for additional data file.","label":[],"Comments":[]}
{"id":219,"text":"Figure S2  Click here for additional data file.","label":[],"Comments":[]}
{"id":220,"text":"Figure S3  Click here for additional data file.","label":[],"Comments":[]}
{"id":221,"text":"Figure S4  Click here for additional data file.","label":[],"Comments":[]}
{"id":222,"text":"Appendix S1  Click here for additional data file.","label":[],"Comments":[]}
{"id":223,"text":"The authors thank Dr. Kazuo Minamikawa, Dr. Akihiro Inano, Ms. Hazuki Ito, and Ms. Momoka Ito for support on conducting the clinical trial.","label":[[124,138,"Study"]],"Comments":[]}
